Skip to main content
OpenTrials
Completed

NCT Number: NCT00270647

Physicians' Health Study II

The use of vitamin E, vitamin C, beta carotene, and/or multivitamins may keep cancer, cardiovascular disease, eye diseases, or cognitive decline from occurring. This randomized clinical trial studied vitamin E, vitamin C, beta carotene, and/or multivitamins to see how well they work compared with placebos in preventing cancer, cardiovascular disease, eye disease, and cognitive decline in male doctors aged 50 years and older.

Completed

Looking for future studies?

Notify Me

Key information

About this study

OBJECTIVES:

Primary

  • To determine whether vitamin E every other day reduces the risk of developing prostate cancer in older healthy male physicians.
  • To determine whether daily vitamin C and/or a multivitamin reduces the risk of total cancer in these participants.
  • To determine whether vitamin E every other day, vitamin C daily, or a multivitamin daily reduces the risk of major cardiovascular events in these participants.

Secondary

  • To determine whether vitamin E and/or multivitamins reduce the risk of developing total cancer, colon cancer, and colon polyps in these participants.
  • To determine whether vitamin E, vitamin C, or multivitamins reduce the risk of myocardial infarction and stroke in these participants.
  • To determine whether vitamin E, vitamin C, or multivitamins reduce the risk of age-related macular degeneration or cataract in these participants.
  • To determine whether vitamin E, vitamin C, or multivitamins reduce the risk of early cognitive decline in participants aged 65 and over.

The Physicians' Health Study II was a randomized, double-blind, placebo-controlled, factorial trial that began in 1997 and ended in 2011. It was designed to test four supplements -- (1) alternate-day vitamin E (400 international units of synthetic alpha-tocopherol) or its placebo; (2) daily vitamin C (500 mg synthetic ascorbic acid) or its placebo; (3) a daily multivitamin (Centrum Silver) or its placebo; and (4) alternate-day beta carotene (50 mg Lurotin) or its placebo -- in the prevention of cancer, cardiovascular disease, eye disease, and early cognitive decline among 14,641 male physicians aged 50 years or older. Participants were randomly assigned in a 2x2x2x2 factorial trial to receive combinations of the four active supplements or their placebos. Pills and/or packaging were provided by BASF Corporation, Pfizer (formerly Wyeth, American Home Products, and Lederle), and DSM Nutritional Products (formerly Roche Vitamins).

The beta-carotene component was discontinued on March 8, 2003; the vitamin E and vitamin C components ended as scheduled on August 31, 2007; and the multivitamin component ended on June 1, 2011.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • DISEASE CHARACTERISTICS:
  • Healthy male physicians practicing in the United States
  • Prior participation in the Physicians' Health Study I allowed
  • PATIENT CHARACTERISTICS:
  • Aged 50 years and over
  • No history of serious illness that would preclude study participation
  • No history of significant adverse events (e.g., rash or allergic reaction) attributed to study agents
  • PRIOR CONCURRENT THERAPY:
  • No other concurrent vitamin and/or multivitamin supplementation
  • No concurrent vitamin K-depleting anticoagulants (e.g., warfarin)

Treatment and study plan

Vitamin E

Dietary Supplement

400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)

Vitamin C

Dietary Supplement

500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)

Multivitamin

Dietary Supplement

Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))

Beta-carotene

Dietary Supplement

50 mg Lurotin or placebo on alternate days (provided by BASF)

Primary outcomes

  1. Prostate cancer

    Time frame: Ongoing

  2. Total cancer

    Time frame: Ongoing

  3. Major cardiovascular events

    Time frame: Ongoing

Secondary outcomes

  1. Cataract

    Time frame: Ongoing

  2. Age-related macular degeneration

    Time frame: Ongoing

  3. Early cognitive decline

    Time frame: Ongoing

  4. Myocardial infarction

    Time frame: Ongoing

  5. Stroke

    Time frame: Ongoing

  6. Colorectal cancer

    Time frame: Ongoing

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Physicians' Health Study II: Trial of Vitamins in the Chemoprevention of Cancer, CVD, and Eye Disease

Acronym: PHS II

Important dates

Study start
1997
Primary completion
2011
Study completion
2011
First posted
Dec 28, 2005
Registry last updated
Feb 28, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.